Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Explore how regulatory strategy, eCTD submissions, health authority interactions, and lifecycle management shape successful pharmaceutical development. This article explains when external expertise adds value, how to choose the right consulting partner, and where stronger planning can reduce regulatory risk.
Learn how EU MDR requirements shape PMS plans, PSURs, PMCF, vigilance, trend reporting, and risk management across device classes. This guide explains practical reporting duties, evidence flows, and regulatory controls that help manufacturers maintain compliant, inspection-ready post-market systems.
Strong pharmacovigilance programs build more than regulatory knowledge. This guide explains how to compare courses, develop GVP skills, strengthen inspection readiness, document competence, and connect training with real drug safety responsibilities across regulated pharmaceutical environments.
Explore what a drug safety role involves, from ICSR processing and MedDRA coding to signal detection, GVP compliance, and career development. Learn which skills employers expect, how responsibilities support inspection readiness, and how professionals can enter the field.
Explore how GMP compliance, quality risk management, CAPA, data integrity, and contamination control connect manufacturing decisions to patient protection. This article explains what inspectors look for, which evidence matters, and how strong quality systems reduce pharmaceutical risk.
Pharmaceutical companies face growing pressure to keep pharmacovigilance systems inspection-ready while managing outsourcing, quality gaps, and complex regulatory requirements. This article explains where external expertise adds value, how to evaluate support, and which controls matter most for sustainable compliance.
Explore how DSMBs review safety signals, assess benefit risk, manage interim analyses, and document trial decisions. This guide explains the evidence, controls, and inspection-ready records pharmaceutical teams need to strengthen clinical trial oversight and support regulatory compliance
Explore how modern safety teams use signal detection, real-world evidence, AI, and controlled review processes to turn complex safety information into traceable regulatory decisions. The article explains practical methods, inspection expectations, and governance controls for stronger pharmacovigilance oversight.
Drug safety requirements vary across regions, making consistent reporting a complex task for global teams. This article explains key regulatory expectations, ICH guidelines, ICSR reporting, MedDRA terminology, and practical considerations for maintaining compliant safety reporting worldwide.
Learn how pharmacovigilance teams evaluate suspected adverse drug reactions using structured approaches, including WHO UMC causality assessment, Naranjo scale principles, and clinical evidence review. Discover how temporal relationship, dechallenge, rechallenge, and alternative causes influence safety decisions.